Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Suzhou Ribo Life Science Co., Ltd.

Home Clinical Trial Sponsors and OrganizationsSuzhou Ribo Life Science Co., Ltd.

Suzhou Ribo Life Science Co., Ltd.

ACTIVE

No.168, Yuanfeng Road, Yushan Town, 江苏省苏州市, 江苏省, Chinawww.ribolia.comHolding51–100 employeesEstablished: 2007-01-18

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

8

1 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2007

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

7

87.5%

Phase 2

1

12.5%

Trial Status Distribution

Active, not recruiting

1

12.5%

Completed

6

75.0%

Recruiting

1

12.5%

Clinical Trials

Trials sponsored by this organization (8)

Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy Participants

Active, not recruiting

Aug 202532 participants

A Study of RBD1016 in CHB Participants

Oct 202348 participants

A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022

May 202380 participants

A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects

Mar 202332 participants

A trial to evaluate safety and characteristics of a substance for treatment of chronic hepatitis

Feb 202348 participants

A Single and Multiple Ascending Doses Study to Evaluate the Safety and Pharmacokinetics of RBD5044

Nov 202272 participants

A Single and Repeated Dose Escalation of RBD1016 in Subjects with Chronic Hepatitis B Virus (HBV) Infection

Aug 202140 participants

A Single Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of RBD1016

Feb 202132 participants

Approvals

No approval data available

News

Ribo Receives EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 Targeting Hepatitis D Virus

- The European Medicines Agency has granted Orphan Drug Designation to RBD1016, an siRNA therapeutic developed by Ribo for treating Hepatitis D Virus infection. - RBD1016 utilizes Ribo's proprietary GalNAc-platform RiboGalSTAR™ to selectively silence key viral factors involved in HDV infection and is currently in Phase II clinical development. - HDV affects an estimated 12-20 million people globally and represents the most severe form of viral hepatitis, with limited therapeutic options currently available. - The designation provides significant regulatory and commercial incentives that enable more rapid progression to patients suffering from this rare and underserved disease.

On this page

Overview
Clinical Trials8
Approvals
News1

Back to Organizations